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Abstract 
Glioblastoma (GBM) is the most common form of primary brain tumour in adults and is 
essentially incurable.  Despite aggressive treatment regimens centred on radiotherapy, 
tumour recurrence is inevitable and is thought to be driven by GBM stem-like cells (GSCs) 
that are highly radioresistant.  DNA damage response pathways are key determinants of 
radiosensitivity but the extent to which these overlapping and parallel signalling components 
contribute to GSC radioresistance is unclear.  Using a panel of primary patient-derived GBM 
cell lines, we confirmed by clonogenic survival assays that GSCs were significantly more 
radioresistant than paired tumour bulk populations.  DNA damage response targets ATM, 
ATR, CHK1 and PARP-1 were upregulated in GSCs and CHK1 was preferentially activated 
following IR.  Consequently, GSC exhibit rapid G2/M cell cycle checkpoint activation and 
enhanced DNA repair.  Inhibition of CHK1 or ATR successfully abrogated G2/M checkpoint 
function, leading to increased mitotic catastrophe and a modest increase in radiation 
sensitivity.  Inhibition of ATM had dual effects on cell cycle checkpoint regulation and DNA 
repair that were associated with greater radiosensitising effects on GSCs than inhibition of 
CHK1, ATR or PARP alone.  Combined inhibition of PARP and ATR resulted in a profound 
radiosensitisation of GSCs which was of greater magnitude than in bulk populations and also 
exceeded the effect of ATM inhibition.  These data demonstrate that multiple, parallel DNA 
damage signalling pathways contribute to GSC radioresistance and that combined inhibition 
of cell cycle checkpoint and DNA repair targets provides the most effective means of 
overcome radioresistance of GSC. 
Word count: 247
Introduction 
Glioblastoma (GBM) is the most common primary brain tumour in adults.  Despite optimal 
treatment consisting of surgical resection followed by radiotherapy with concomitant and 
adjuvant temozolomide chemotherapy, median survival remains dismal at 12–15 months (1). 
Responses to treatments are inevitably followed by relapse, typically within the maximally 
irradiated volume (2,3). In GBM tumourigenic cells display complex clonal dynamics in which 
genetically distinct sub-clones have variable serial repopulating activity in vivo (4,5). Such a 
functional readout is likely to represent activity of self-renewing GBM ‘stem-like’ cells (GSCs) 
whose competitive self-renewal ability varies on the basis of frequency and/or quantitative 
features and underpins the evolution of resistant disease (6). Consistent with this GSCs that 
express stem cell markers such as CD133, SSEA-1 (CD15), Nestin, SOX2 and Olig2 (7-10) 
are more resistant to radiotherapy and conventional chemotherapy than more differentiated 
epigenetically stable ‘tumour bulk’ cells (10-14).  Thus there is an urgent need to develop 
targeted treatment strategies that will overcome the innate resistance of GSCs, improve 
local tumour control and extend patient survival. 
Radiotherapy is a vital therapeutic modality for GBM which at a cellular level causes single 
and double stranded DNA breaks that evoke a multifaceted DNA damage response (DDR).  
At the apex of the DDR lie the serine/threonine protein kinases ataxia telangiectasia mutated 
(ATM) and ataxia telangiectasia and Rad3-related (ATR) which maintain genomic integrity 
by activating cell cycle checkpoints and DNA repair pathways (15).  ATM is mainly activated 
by DNA double-strand breaks (DSBs) whereas ATR responds to single-stranded regions of 
DNA generated at stalled replication forks  and during processing of DSBs by nucleases (16-
19).  The MRN (MRE11-RAD50-NBS1) complex has key roles in sensing and processing 
DSBs as well as activating ATM and ATR (20).   ATR activates cell cycle checkpoint kinase 
proteins including CHK1 whereas ATM functions primarily through activation of CHK2. 
These downstream checkpoint kinases activate G1 and G2/M cell cycle checkpoints through 
phosphorylation of phosphatases CDC25A, CDC25C and kinases CDK1 and Wee1 that 
regulate cell cycle progression (21).  Additionally, ATM promotes repair of a subset of DSBs. 
Poly(ADP-ribose) polymerase (PARP) facilitates repair of radiation induced single strand 
breaks (SSBs) and the radiosensitising effects of PARP inhibitors are well characterised 
(22).  This brief summary illustrates key components of the complex network of overlapping 
and parallel DDR pathways that dictates cellular outcomes after radiation treatment. 
There is growing evidence that DDR signalling is upregulated in GBM and integral to GSC 
radioresistance.   Analysis of GBM clinical samples has revealed high levels of p-ATM, p-
CHK1, p-CHK2 and PARP1 compared to normal brain tissue (23,24).  Furthermore, basal 
levels of p-CHK1, p-CHK2 and Rad17 have been shown to be higher in CD133+ GSCs 
compared to non-tumourigenic CD133- populations, a finding that was associated with  
radioresistance of the GSC population (10).  However, subsequent studies have either failed 
to show differences in DNA repair capacity based on CD133 status or revealed increased 
radiosensitivity of CD133+ GSCs compared to established GBM cell lines (25,26).  Such 
discrepancies may reflect methodological differences or comparisons between non-isogenic 
cell lines.  Indeed, we have recently demonstrated that radioresistance of GSC populations 
is associated with enhanced ATM dependent DSB repair proficiency (27). 
Currently there is intense research into the development of small molecule inhibitors of DDR 
proteins (DDRi), one aim of which is to increase the therapeutic index of standard treatments 
(28).  This is driven by several factors: (i) DNA is the major target for many anticancer 
therapies, (ii) constitutive activation of DDR is frequently observed in cancers (29) and (iii) 
activation of DDR is associated with resistance to cytotoxic therapies. Several preclinical 
studies have successfully utilised DDRi to increase chemo- and radiosensitivity in GBM 
models but these results were not substantiated in the treatment resistant GSC population 
(30-34).  More recently we have shown the ATM inhibitor KU55933 to be a potent 
radiosensitiser of GSC (27) and inhibition of PARP has also been shown to overcome 
radioresistance of GSCs (35).  These findings corroborate and extend the landmark study by 
Bao and colleagues in which inhibition of CHK1 and CHK2 using debromohymenialdisine 
was shown to enhance the radiosensitivity of GSCs (10).   
The observation that GSCs exhibit upregulated DDR signalling provides both opportunities 
and challenges. Whilst targeting individual components of this complex network can increase 
the radiosensitivity of GSC, the relative contributions of these components and the 
implications of multiple DDR pathways and mechanisms contributing to radioresistance 
remain unexplored.  We addressed this by utilising paired, primary, patient derived GBM cell 
lines cultured to enrich for or deplete the GSC population (‘GSC’ and ‘bulk’ populations 
respectively).  We show that GSCs express higher total and activated levels of DDR targets 
than bulk populations and that this phenotype is maintained in orthotopic xenograft models 
and GBM patient specimens.  Our mechanistic studies highlight rapid activation of cell cycle 
checkpoint and enhanced DNA repair as key determinants of GSC radioresistance.  We 
show that, although selective inhibition of either pathway increases radiosensitivity of GSC, 
effects are limited by reciprocity between these signalling conduits.  Accordingly, combined 
inhibition of ATR and PARP1 significantly enhanced the radiosensitivity of GSCs, and the 
magnitude of this effect was greater than in bulk populations. We propose that targeting of 
parallel DDR pathways is required to maximise radiosensitisation of GSCs and optimise 
outcomes for GBM patients. 
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Materials and Methods 
Derivation and maintenance of primary and patient derived GBM cell lines 
Primary patient derived GBM cell lines E2, G7, R10, R15 and R24 were derived from freshly 
resected tumour specimens and maintained as described previously (22,36).  Patient 
consent was sought before surgery and tissue collection was approved by the local regional 
Ethics Committee (LREC ref 04/Q0108/60) and compliant with the UK Human Tissue Act 
2004 (HTA Licence ref 12315).  Each cell line was cultured in pairs either on Matrigel TM (Life 
Technology) coated flasks in AdvDMEM F12 medium (Gibco) supplemented with 1% B27 
(Invitrogen), 0.5% N2 (Invitrogen), 4µg/ml heparin, 20ng/ml bFG, 20ng/ml EGF (Sigma), and 
1% L-Glutamine to maintain the GSC population or in MEM (Gibco) supplemented with 10% 
FBS Sigma, 1% L-glutamine and 1% sodium pyruvate to deplete the GSCs and generate a 
differentiated tumour bulk population.  All cell cultures were maintained at 370C, 5% CO2.  
Cell lines were utilised between 6-15 passages and then discarded.   
Generation of orthotopic tumours and immunohistochemistry 
Tumours were generated by injecting 1 x 105 cells in CD1 nude mice as described 
previously (37), and in supplementary materials and methods.   Immunohistochemistry was 
performed on paraffin embedded sections.  Following antigen retrieval sections were 
incubated with anti-Ki67, PARP-1 or p-ATM antibodies overnight followed by incubation with 
secondary antibodies.  Staining was visualised by application of DAB. 
Drug treatment and radiation 
ATM inhibitor KU-55933 (Tocris bioscience), ATR inhibitor VE821, PARP inhibitor olaparib, 
CHK1 inhibitors SCH900776 and CHIR-124 (Selleckchem), hydroxyurea and aphidicolin 
(Sigma) were all dissolved in DMSO.  For drug-radiation combination studies, cells were 
exposed to fresh media containing the inhibitor or relative DMSO control for 1 hour prior to 
irradiation in tissue culture vessels using an XStrahl RS225 cabinet at room temperature 
with 195kV/15mA X rays producing a dose rate of 1.6 Gray per minute.  For UV studies, 
media containing the drug was removed after one hour and cells were irradiated using a UV 
Stratalinker (Stratagene). 
Clonogenic and neurosphere assays 
Paired GSC and bulk population from E2 and G7 cell lines formed countable colonies and 
were seeded at a density of 250 cells per well in Matrigel coated 6 well dishes for 24 hours.  
Wells were treated with the inhibitors or relative DMSO control for 1 hour followed by mock 
or 1-5Gy irradiation. Cells were then incubated for a further 24 hours followed by 
replacement with fresh media. E2 and G7 colonies were fixed after 2 or 3 weeks respectively 
in methanol followed by staining with crystal violet.  Colonies consisting of minimum 50 cells 
were counted manually and using an automated colony counter (GelCountTM, Oxford 
Optronix).  Clonogenic survival data were fitted using a linear quadratic model and SER0.37 
and SF4Gy values were calculated from the fitted curve.  ANOVA test was used to analyse 
differences between clonogenic survival curves. 
For neurosphere assay 10 GSCs were seeded into each well of a 96 well plate in 100µL 
medium containing the drug or relative DMSO control for 1 hour followed by mock or 2Gy 
irradiation.  48 hours later a further 150 µL of fresh media was added per well. Neurospheres 
were manually counted under 5x magnification after 3 or 4 weeks for G7 and E2 GSC 
respectively.  
Immunofluorescence 
Paired bulk and/or GSCs were plated on coverslips coated with Matrigel and treated with 
radiation alone or in combination with the inhibitors for 24 hours.  Cells were fixed and 
incubated with γ-H2AX or p-His H3 S10 antibodies overnight at 4oC followed by incubation 
with secondary conjugated antibodies. Nuclei were counterstained with Vectashield 
containing DAPI. Images were acquired using Zeiss LSM 710 confocal microscope and 
analysed using Velocity software (PerkinElmer).  γ-H2AX foci data are presented as box and 
whisker plots from 3 independent experiments unless otherwise stated and analysed using 
Mann Whitney U-test as they was not normally distributed.  
Flow cytometry and cell death 
For analysis of mitotic population, cells were treated and fixed with 70% ethanol and 
incubated with p- H3 S10 antibody followed by γ-H2AX antibody and analysed using flow 
cytometry.  Combined annexin V and PI analysis was carried out as described preciously.  
Analysis of GSC markers was carried out using CD133 and CD15 (Miltenyi biotech).  Data 
was analysed using FlowJo software (Tristar).  Analysis of caspase 3/7 activity was carried 
out using Caspase-Glo 3/7 kit (Promega). 
Western blotting 
For immunoblotting whole cell lysates were prepared and processed in SDS buffer, blotted 
onto membranes and probed with primary antibodies (supplementary material and methods) 
overnight followed by appropriate secondary antibodies for 1-3 hours.  Bound antibodies 
were visualised using chemiluminescence kit (Thermo Scientific).  
Statistical Analyses 
All experiments were repeated 3 times unless otherwise stated and data points reported as 
mean +/- SEM. Statistical analysis and graphs were produced using Minitab 16 and 
Graphpad Prism 6.  Unpaired t-test or one sample t-test were used to generate p values. 
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Results 
GSC populations are radioresistant  
We have previously characterised two primary GBM cell lines (E2 and G7) (27,37).  Using 
the same techniques three additional primary GBM cell lines (R10, R15 and R24) were 
expanded by culturing under selective media to enrich for or deplete the GSC population. 
We demonstrated that GSC enriched populations of E2, G7 (27,37), R10 and R24 generate 
orthotopic tumours in immunodeficient mice that recapitulate the human disease, whereas 
GSC depleted, tumour bulk populations do not (supplementary Figure S1). While the neural 
stem cell markers nestin, SOX2, CD133, Olig2 and CD15 were heterogeneously expressed 
between different GSC cultures, expression of these markers was consistently increased in 
GSCs compared to bulk populations (Figure 1A and 1B).  Clonogenic survival assays in E2 
and G7 cell lines confirmed GSC cultures to be more radioresistant than paired bulk 
populations. Dose modifying factors calculated at 37% survival (DMF0.37) showed that E2 
and G7 GSCs were more radioresistant than corresponding bulk populations by factors of 
1.36 (p=0.001) and 1.44 (p<0.001) respectively (Figure 1C-E).  Radioresistance of GSC 
populations was confirmed by comparing surviving fraction at 4Gy (SF4Gy, supplementary 
Table 1).  These findings were consistent with the observation that E2 and G7 GSCs were 
refractory to cell death as measured by Annexin-V and propidium iodide staining following 
treatment with high radiation doses (15 and 30 Gy, Figure 1F, supplementary Figure S2). 
Caspase 3/7 activity assays supported the assertion that GSC populations are extremely 
resistant to radiation induced apoptotic cell death (Figure 1G). 
GSCs express high levels of DDR targets under basal conditions and activate CHK1 
rapidly following IR 
DDR targets have previously been shown to be upregulated and associated with GSC 
radioresistance (10,27,35).  We explored this further in our GSC and bulk culture models 
and observed an overall pattern of higher levels of total and phosphorylated CHK1 (S345) 
and ATR (S428) in GSCs compared to bulk populations in primary GBM cell lines (Figure 
2A).  Similarly, higher levels of PARP-1 and phosphorylated ATM (p-ATM, S1981) were also 
observed in the majority of the GSC populations (Figure 2A).  To confirm these findings in 
vivo we generated xenograft tumours from E2 and G7 GSC using an orthotopic mouse 
model.  Analysis of tumour sections revealed a heterogeneous pattern of p-ATM (S1981) 
and PARP-1 staining highlighting differential protein expression between different cell 
populations (Figure 2B).   PARP-1 staining in G7 tumours was abundant and homogeneous, 
consistent with previous reports proposing PARP-1 as a GBM marker (24). These findings 
were reproduced in a clinical GBM specimen, which exhibited marked p-ATM and PARP-1 
expression in the majority of tumour cells (Figure 2B).  These data illustrate collective 
induction of DDR targets in GSC populations under basal conditions in vitro and in a 
subpopulation of GBM cells in vivo. 
We next sought to investigate how differences in basal CHK1 levels between GSC and bulk 
populations affect the DDR.  Irradiation of E2 and G7 GSCs evoked pronounced activation of 
CHK1 (S345 phosphorylation) within 15 minutes that was maintained for at least 3 hours 
(Figure 2C, supplementary Figure S3). In contrast, bulk cells failed to activate CHK1 despite 
similar levels of DNA damage (γ-H2AX). CHK2 activation (T68 phosphorylation) was similar 
in E2 GSC and bulk populations although differences were observed between G7 bulk and 
GSC populations (supplementary Figure S3).  We explored the possibility that enhanced 
activation of CHK1 in GSC could be caused by ‘priming’ of the MRN (MRE11, RAD50, 
NBS1) DNA damage sensor complex under basal conditions.  No differences in total or 
phosphorylated MRE11 and NBS1 between GSC and bulk populations were observed under 
basal conditions or following irradiation, but modest upregulation of RAD50 was observed in 
E2 and G7 GSCs following irradiation (Figure 2C, supplementary Figure S3). The possibility 
that CHK1 activation was delayed in bulk cells was excluded by demonstrating that S296 
phosphorylation of CHK1 was attenuated in E2 and absent in G7 bulk cells but maintained in 
both GSC cultures at 6, 12 and 24 hours after irradiation (Figure 2D). Enhanced CHK1 
activation in GSC was not only a radiation specific phenomenon: E2 and G7 bulk cells also 
failed to activate CHK1 (S345 and S296 phosphorylation) in response to UV, hydroxyurea or 
aphidicolin treatments despite levels of γ-H2AX induction that were comparable to GSC 
populations (Figure 2E, supplementary Figure S3). 
Rapid induction of CHK1 in GSCs is associated with enhanced G2/M cell cycle 
checkpoint activation 
We next investigated the impact of rapid CHK1 activation on cell cycle checkpoint responses 
of GSCs.  Both E2 and G7 cell lines were refractory to radiation induced G1/S checkpoint 
activation, consistent with frequent deregulation of p53 signalling pathways in GBM (38) 
(supplementary Figure S4).  However, analysis of the G2/M checkpoint by flow cytometric 
quantification of mitotic cells with S10 phosphorylation on histone H3 (p-His H3) revealed 
that GSC activated G2 arrest significantly more efficiently than paired bulk populations, 
requiring less time to reduce the mitotic cell population by 50% following IR treatment 
(Figure 3A, supplementary Figure S5).  Intriguingly, E2 bulk cells failed to fully activate the 
G2/M checkpoint even at three hours.  Moreover, a dose response study revealed that 
depletion of mitotic cell fraction by 75% occurred after significantly lower radiation doses in 
E2 and G7 GSC compared to bulk populations (Figure 3B, supplementary Figure S5). E2 
and G7 bulk cells were also released from the G2/M checkpoint earlier than GSC. Based on 
these observations we hypothesised that the increased radiosensitivity of tumour bulk cells 
(Figure 1) might be at least partly explained by these cells entering mitosis carrying 
unrepaired DNA damage (see also Figure 5 and Figure 6). 
Radiosensitising effects of CHK1 inhibition are more pronounced in GBM bulk cells 
than GSCs 
Reasoning that radioresistance of GSCs might be driven by enhanced CHK1 mediated 
activation of the G2/M checkpoint, we hypothesised that inhibition of CHK1 would abrogate 
the G2/M checkpoint and increase radiosensitivity. To investigated this we utilised SCH 
900776 (SCH) a well characterised CHK1 specific inhibitor which had no significant effect on 
CHK2 activity as highlighted by unaltered phosphorylation of T68 (Figure 4A-C) (39,40).  As 
expected, SCH treatment alone inhibited CHK1 S296 autophosphorylation in a dose 
dependent manner and induced CHK1 S345 phosphorylation through CHK1 dependent 
inhibition of the PP2A phosphatase feedback loop (41) (Figure 4A and 4C, supplementary 
Figure S6).  Treatment of E2 GSCs with SCH resulted in enhanced induction of CHK1 S345 
phosphorylation by UV or IR along with increased γ-H2AX levels reflecting increased DNA 
damaging signalling in response to CHK1 inhibition (Figure 4A-C and supplementary Figure 
S6).  Interestingly, induction of CHK2 T68 phosphorylation was also observed following 
combined treatment with SCH plus IR suggesting compensatory activation of CHK2 
following CHK1 inhibition (Figure 4C) (42).  In addition SCH treatment alone generated a γ-
H2AX signal highlighting a basal function of CHK1 in maintaining genomic stability (43).  
Additional biomarkers of CHK1 inhibition included downregulation of phosphorylated Wee1 
(S642) and CDC25C (T48) whilst upregulation of CDC25A was observed following SCH 
treatment alone and augmented in combination with radiation, consistent with enhanced cell 
cycle progression despite the presence of damaged DNA (Figure 4B and 4C, supplementary 
Figure S6). 
Since our earlier results showed that GSCs activate the G2/M cell cycle checkpoint rapidly in 
response to IR (Figure 3), we hypothesised that CHK1 inhibition would abolish this and thus 
overcome the radioresistant phenotype of the GSC populations.  Indeed, SCH treatment 
abrogated radiation induced G2 arrest in E2 and significantly attenuated it in G7 GSCs, while 
SCH treatment in the absence of radiation was sufficient to drive E2 and G7 GSCs into 
mitosis (Figure 4D).  Importantly, clonogenic survival assays confirmed significant 
radiosensitisation of E2 and G7 GSC by CHK1 inhibition as illustrated by sensitisation 
enhancement ratios at 37% survival (SER0.37) of 1.9 and significant reductions in surviving 
fractions at 4Gy (SF4Gy) in both cell lines (Figure 4E and 4F).  Despite the limited ability of 
bulk populations to phosphorylate CHK1 and induce G2/M checkpoint activation in response 
to radiation, a similar or greater magnitude of radiosensitisation (SER0.37=2.3-2.4) was 
observed in bulk populations treated with SCH.  This unexpected observation was confirmed 
using an alternative CHK1 inhibitor CHIR-124 (44) (supplementary Figure S7).  While these 
data support the assertion that CHK1 inhibition has therapeutic potential in GBM, the 
observation that overexpression and constitutive activation of CHK1 in GSCs was not 
associated with increased radiosensitisation by CHK1 inhibitors indicates that additional 
mechanisms could be responsible for limiting the radiosensitisation effects of CHK1 
inhibition in the GSC population. 
Inhibition of CHK1 radiosensitises GSC through a mechanism involving mitotic 
catastrophe 
Our subsequent studies were aimed at investigating the mechanisms responsible for (i) GSC 
radiosensitisation by CHK1 inhibition and (ii) enhanced radiosensitisation of bulk cells.  Initial 
analysis of DNA damage in E2 GSCs using flow cytometry highlighted a significant increase 
in the γ-H2AX positive cell population following combined SCH and IR treatment compared 
to individual treatments alone (Figure 5A and 5B).  Interestingly, SCH treatment alone 
induced a γ-H2AX response, confirming our earlier results (Figure 4A-C).  Since this signal 
was observed predominantly in S-phase cells, we inferred that CHK1 inhibition exacerbates 
replication stress in GSCs.  While induction of γ-H2AX was also observed in the paired E2 
bulk population following treatment with SCH and IR (Figure 5C), the magnitude of this effect 
was significantly lower than in GSCs.  The observation that enhanced generation of DNA 
damage did not translate to enhanced radiosensitisation of GSCs (Figure 4E and 4F) led us 
to investigate the manner in which the different populations responded to this S-phase 
dependent DNA damage. Since SCH treatment also inhibited the G2/M checkpoint (Figure 
4D) we first investigated whether treated GSCs would enter mitosis with damaged DNA. 
Analysis of γ-H2AX in mitotic (p-His H3) cells revealed induction by SCH of a distinct 
population of mitotic cells with high γ-H2AX signal. This population was significantly 
increased after combined treatment with IR (Figure 5D and 5E).  Immunofluorescence 
analysis confirmed these results, demonstrating a distinct mitotic cell population with intense, 
pan-nuclear γ-H2AX staining (middle panel, Figure 5F).  This is likely to represent cells in the 
initial stages of mitotic catastrophe, which was clearly visible in a separate population of 
mitotic cells characterised by loss of membrane integrity and fragmented morphology 
(bottom panel).  Both populations were augmented in GSCs following combined treatment 
with SCH and IR relative to either treatment alone.  In addition, we evaluated the 
consequence of mitotic division in cells with damaged DNA and found a significant increase 
in the percentage of GSCs harbouring one or more micronucleus following the combined 
treatment (Figure 5G).  Taken together, our data demonstrate that CHK1 inhibition sensitises 
GSC to IR by preventing G2/M checkpoint activation, allowing mitotic entry of cells bearing 
damaged DNA resulting in mitotic catastrophe and genomic instability. 
Limited radiosensitisation of GSCs by CHK1 inhibition is explained by enhanced DNA 
repair 
We next sought to identify the mechanism that could be responsible for limiting the 
radiosensitising effects of CHK1 inhibition in GSCs by comparing effects in paired bulk cell 
populations in which SCH had shown more pronounced radiosensitising effects (Figure 4E 
and 4F).  Despite our previous data showing that combined treatment of E2 cells with SCH 
and IR generated less DNA damage in bulk cells than in GSCs (Figure 5A-C), this treatment 
resulted in a significant increase in overall and mitotic specific γ-H2AX positive cells 
compared to radiation or SCH treatment alone in G7 bulk cells (Figure 6A and 6B), the 
magnitude of which was significantly greater than that observed in the paired GSC 
population. The percentage of bulk cells exhibiting mitotic catastrophe and micronuclei after 
treatment with SCH +/- IR was also significantly greater than in the corresponding GSC 
population (Figure 6C and 6D).  Since micronuclei are a direct consequence of mitotic 
division in cells with unrepaired DNA DSBs, these observations are strongly supportive of 
the theory that GSC exhibit significantly enhanced DNA repair capacity when compared with 
bulk cells. This theory is corroborated by the observation that a significantly higher 
percentage of bulk cells than GSCs harbour micronuclei under basal conditions (Figure 6D).  
To substantiate this hypothesis, detailed analysis of DNA DSB repair was conducted by 
quantification of γ-H2AX foci in CENPF positive (G2/M) and negative (G1) cells 24 hours 
after high dose radiation (10 Gy). This clearly showed increased repair proficiency of GSC 
compared to bulk cells (Figure 6E and 6F), supporting our earlier hypothesis that enhanced 
DNA repair is responsible for the attenuated radiosensitising effects of CHK1 inhibition that 
were observed in E2 GSCs. Enhanced DNA repair by GSC thus appears to compensate for 
the significant increase in DNA damage observed in GSCs treated with radiation and CHK1 
inhibition (Figure 5C). 
Optimum radiosensitisation of GSCs through parallel inhibition of DNA damage 
response pathways 
In order to identify the optimum targets for GSC radiosensitisation we evaluated small 
molecule inhibitors of additional DDR proteins that were up-regulated in GSCs (Figure 2A).  
DNA repair was targeted using the PARP inhibitor olaparib, cell cycle checkpoints were 
inhibited using the ATR inhibitor VE821 and combined targeting of cell cycle checkpoints 
and DNA repair was evaluated using the ATM inhibitor KU55933.  Results in E2 cells 
showed that ATR inhibition sensitised GSC and bulk populations equally although there was 
a trend towards increased radiosensitisation of bulk cells (Figure 7A and 7B).  SER0.37 values 
for ATR and CHK1 inhibition were comparable.  In contrast, inhibition of PARP or ATM 
revealed a trend towards increased radiosensitisation of GSC. The ATM inhibitor KU55933 
proved to be the most potent radiosensitiser of GSC (SER0.37=2.60, Figure 7B). 
To understand the reasons for the different magnitudes of GSC radiosensitisation by the 
DDR inhibitors we investigated their effects on cell cycle checkpoints and DNA repair.  
Whereas inhibition of either ATR or CHK1 completely ablated radiation induced G2/M 
checkpoint activation (Figure 7C), inhibition of ATM had only a partial effect. In contrast, 
ATM inhibition significantly impaired repair of radiation induced DSBs as demonstrated by a 
significant increase in the number of unresolved γ-H2AX foci 24 hours post-irradiation 
(Figure 7D).  A similar effect on DNA repair was observed following PARP inhibition.  
Considering that ATM inhibition was associated with the greatest radiosensitisation of GSCs 
we hypothesised that dual inhibition of cell cycle checkpoint activation and DNA repair might 
provide optimum radiopotentiation.  This was investigated by concomitant inhibition of DNA 
repair and cell cycle checkpoint function by combined treatment with inhibitors of PARP and 
ATR. As predicted, the radiosensitising effect of this combination in GSCs exceeded that of 
any of the inhibitors individually (SER0.37=3.20, Figure 7E) and was significantly greater than 
that observed in the paired bulk cells.  This is likely to be due to increased unrepaired DSBs 
since combined inhibition of ATR and PARP was shown to be associated with a significant 
increase in γ-H2AX foci in GSCs compared to the bulk population (supplementary Figure 
S8).  To support the clinical relevance of this result we performed neurosphere formation 
assays using E2 GSCs and confirmed that dual inhibition of ATR and PARP achieved 
maximum potentiation of the inhibitory effects of radiation on neurosphere formation (Figure 
7F).  Taken together our results show that optimal radiosensitisation of GSCs is achieved 
through parallel inhibition of DDR pathways. 
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Discussion 
GBM are heterogeneous tumours that are thought to be dependent on a cellular hierarchy 
that includes a privileged GSC subpopulation resistant to conventional therapy and capable 
of tumour propagation and growth.  Uncertainty over the ideal model(s) in which to study 
radiation responses of the GSC population may account for the disparities in the findings of 
the various published studies (10,25,26).  In keeping with our previous studies we generated 
paired cultures of primary, patient derived GBM cell lines (10,35) in which the GSC 
population was either enriched or depleted (27). The use of sorted cell populations based on 
a specific stem cell marker such as CD133 has been questioned because both CD133+ and 
CD133- cells were capable of generating tumours in vivo (45).  In addition, our study shows 
that stem cell markers are heterogeneously expressed. Thus the GSC “signature” is likely to 
be more complex, modulated by the cellular microenvironment and governed by multiple 
parameters including epigenetic and genetic aberrations which impact upon the expression 
of key regulatory proteins.  In keeping with this interpretation, a recent publication highlights 
four core neurodevelopment transcription factors that are crucial to GSC maintenance and 
tumourigenicity (46). 
Our study shows that GSCs are more radioresistant than paired bulk populations and exhibit 
higher expression of total and activated DDR targets under basal conditions.  The reason for 
this is unclear; we speculate that it may reflect an endogenous response of neural stem cells 
to DNA damage which is subsequently maintained as part of mutagenic selection and the 
malignant phenotype.  In addition, genetic differences between GSCs and bulk cells may 
affect cellular biochemistry, possibly accounting for lower proteasomal activity in GSCs 
contributing to higher levels of DDR targets (47).  More recently increased levels of reactive 
oxygen species have been proposed as a mechanism responsible for upregulated PARP-1 
in GSCs (35). 
One surprising observation was the apparent lack of CHK1 activation in bulk cells exposed 
to IR.  This observation and the slower DNA repair kinetics of these cells might explain why 
they are significantly more radiosensitive than the GSC population. Whilst our results 
support this, it should be emphasised that the bulk cells remain relatively radioresistant, 
suggesting that alternative pathways might compensate for the lack of CHK1 activation and 
attenuated DDR.  Indeed, non-canonical DDR pathways including NOTCH, TGFβ and 
receptor tyrosine kinase signalling have all been associated with GBM radioresistance and 
may be activated in these cells (reviewed in (48).  Alternatively, bulk cells may rely on DNA 
damage tolerance (DDT) mechanisms which utilise translesion synthesis polymerases to 
bypass lesions for repair at later time points (49).  This provides a mechanism to tolerate 
DNA damage allowing cells to continue replicating and might explain the survival of bulk 
cells following IR despite the lack of checkpoint activation and early checkpoint release. 
The MRN complex is a crucial DNA damage sensor that is recruited to and participates in 
DNA DSB repair.  Although our results show no significant differences in the levels of total 
and phosphorylated components of the MRN complex between GSC and bulk populations, 
the rate at which the complex is recruited to damaged site and catalytic activity of specific 
components may be greater in the GSCs contributing to the enhanced radioresistance of 
these cells. 
Our study shows that multiple DDR targets including ATR, ATM, CHK1 and PARP-1 are 
upregulated in GSCs compared to the bulk population, and that some are also preferentially 
activated.  Although some of these targets have overlapping functions, individually they have 
distinct roles which suggest that multiple DDR pathways contribute to GSC radioresistance.  
Our studies showed that both GSC and bulk populations were radiosensitised by CHK1 or 
ATR inhibition despite higher expression and activity of these proteins in GSCs. This led us 
to propose that alternative DDR pathways might mitigate the radiosensitising effects of 
CHK1 or ATR inhibition in the GSC populations. In support of this explanation, inhibition of 
ATM, with its dual functions in DNA repair and cell cycle checkpoint activation, yielded the 
most potent single agent radiosensitisation of GSCs.  Importantly we confirmed this 
hypothesis by demonstrating that combined inhibition of ATR and PARP generated 
maximum radiosensitisation, and that this effect was of significantly greater magnitude in 
GSCs than in bulk populations. Inhibition of PARP resulted in a significant increase in DNA 
DSBs, which were likely to have been generated during S-phase from unrepaired DNA 
SSBs. In the context of ATR inhibition these cells were unable to activate the G2/M cell cycle 
checkpoint to entered mitosis carrying high levels of unresolved DSBs.  Thus we propose 
that GSC radioresistance is driven by both enhanced cell cycle checkpoint activation and 
DNA repair, and therefore optimal radiosensitisation is only achieved by dual inhibition of 
both pathways. 
Our data strongly support further pre-clinical evaluation of ATR and PARP inhibitors in 
combination with IR as a potential treatment for GBM.  This is an entirely novel approach 
that to our knowledge has not been investigated in any cancer models.  Clearly there will be 
concerns over the potential in vivo toxicity of this combination treatment modality: ATR is 
essential for tissue homeostasis, highlighted by embryonic lethality of ATR knockout mice, 
whereas PARP1 knockout in mice is less deleterious.  However, clinical experience with 
PARP inhibitors has been extremely promising; it is tolerated well as a single agent and 
clinical studies in combination with radiation are progressing.  To our knowledge only one 
clinical study is currently recruiting patients to explore ATR inhibition as a radiosensitising 
strategy in advanced solid tumours (www.clinicaltrials.gov).  However, a pre-clinical study 
using the ATR inhibitor VE822 has demonstrated radiosensitisation of pancreatic tumours in 
mice with no apparent in vivo toxicity (50).  The high proliferation indices of most GBM is 
predicted to render them more sensitive to the combination of radiotherapy, PARP inhibition 
(33) and ATR inhibition, and the GSC specific radiosensitisation mechanisms outlined in this 
paper are associated exclusively with S, G2 and M phases of the cell cycle.  Since normal 
brain tissues are comprised almost entirely of non-replicating, post-mitotic cells with intact 
G1/S checkpoint and DNA repair pathways, we predict that the radiosensitising effects of the 
proposed combination will be exerted exclusively upon GBM tumour cells, and will have 
particular impact on the radioresistant GSC population.     
In summary, our study provides the first detailed examination of DDR responses in GSCs 
and has important implications for the management of GBM.  Our results support the notion 
that GSCs are profoundly radioresistant and identify a novel drug combination strategy 
targeting both cell cycle checkpoint and DNA repair functions that has potential to overcome 
this.  Future studies will focus on in vivo characterisation of this strategy and will identify 
optimal radiation/drug combination scheduling to take forward to phase I clinical trials in 
GBM patients. 
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Figure legends 
Figure 1.  GSCs are radioresistant with defective DDR 
(A)  Enrichment of stem cell markers SOX2, Nestin, CD133 and Olig2 under GSC culture 
condition compared to paired bulk populations in primary patient derived GBM cell lines.  (B) 
Flow cytometry plots and summary showing relative expression of CD133 and CD15 in E2 
and G7 GSC and bulk populations. (C-D)  Clonogenic survival assays showing E2 and G7 
GSCs are more radioresistant compared to the paired bulk populations. (E) Calculation of 
dose modifying factor (DMF) at 37% survival comparing E2 and G7 GSC vs bulk populations 
and p value  associated with comparisons of DMF.  (F) Plots summarising combined annexin 
V and PI staining  or (G) fold induction in caspase 3/7 activity at 48 hours in E2 and G7 GSC 
and bulk populations following  treatment with 15 or 30 Gy ionising radiation. Error bars 
show mean ± SEM from n=3 independent experiments, * p<0.05, NS=non-significant. 
Figure 2. GSCs have upregulated DDR proteins under basal condition and active 
CHK1 rapidly following IR 
(A) Analysis of multiple DDR proteins under basal conditions in GSC or bulk populations in a 
panel of primary patient derived GBM cell lines.  Loading control as shown in Figure 1A.  (B) 
Immunohistochemistry analysis of orthotopic tumour section generated from E2 and G7 
GSC and GBM patient specimen showing PARP1 and p-ATM staining. (C) Western blots 
showing rapid activation of DNA damage response markers at early time points in E2 GSC 
compared to bulk populations following 5Gy IR.   (D) 24 hour time course highlighting CHK1 
and phosporylated CHK1 levels in E2 and G7 paired GSC and bulk populations following 
5Gy IR.  (E) Response of E2 bulk and GSC populations to various activators of CHK1: 
IR=5Gy, 1hr; UV=10JM-2, 1hr; HU=10mM, 3hr; Aphidicolin=1mM, 3hr, (* longer exposure). 
Figure 3.  Rapid activation of G2/M cell cycle checkpoint in GSCs following IR 
Summary of flow cytometry data analysing mitotic p-His H3 S10 cell population to measure 
G2/M cell cycle checkpoint in paired E2 and G7 GSC and bulk populations. (A) 3 hour time 
course following 5Gy IR treatment showing a rapid activation of G2/M checkpoint in GSCs 
as measured by the time required to reduce mitotic population by 50%.  (B) IR dose 
response showing E2 and G7 GSC populations require significantly lower dose of radiation 
compared to the bulk cells to activate G2/M checkpoint by 75% relative to unirradiated cells. 
(C) 12 hour IR time course showing E2 and G7 bulk cells exit the G2/M checkpoint 
significantly quicker than the paired GSC population as measured by the time required for 
mitotic cell population to return to baseline levels.  Plots show mean ± SEM, n≥3 
independent experiments. 
Figure 4. GSCs are radiosensitised by the CHK1 inhibitor SCH900776 (SCH) 
(A) Inhibition of CHK1 in E2 GSCs following 1 hr pre-treatment with various concentrations 
of SCH followed by 120Jcm-2 UV for 1hr.  (B)  Time course showing abrogation of IR induced 
CHK1 activation by pre-treatment of E2 GSCs with 3µM of SCH for 1hr (* denotes longer 
exposure). (C) Analysis of multiple biomarkers of CHK1 inhibition at 24 hours in E2 GSCs 
treated with various concentrations of SCH for 1hr followed by 5Gy IR.  (D)  Plots 
summarising flow cytometry data showing inhibition of IR induced G2/M checkpoint 
activation in E2 and G7 GSCs treated with 3µM SCH for 1hr followed by 5Gy IR, (mean ± 
SEM from n≥3 independent experiments, *p<0.05, **p<0.01,***p<0.001 relative to IR alone. 
(E)  Clonogenic survival curves showing radiosensitisation of E2 and G7 GSC and bulk 
populations following 3µM of SCH treatment. (F) Summary of clonogenic data showing SER 
of GSC and bulk populations at 37% survival and SF at 4Gy in the presence or absence of 
SCH. * denotes p<0.05 based on the 95% confidence intervals between SER of GSCs and 
bulk population or SF of GSC or bulk  populations plus or minus SCH treatment. NS=Non 
significant. 
Figure 5. Inhibition of CHK1 increases DNA damage, induces mitotic catastrophe and 
leads to genomic instability in irradiated GSC 
(A) Representative flow cytometry plots showing the percentage of γ-H2AX positive cells in 
E2 GSC following 3µM SCH treatment for 1 hr followed by 5Gy IR treatment for 24 hours.  
(B) Bar chart summarising the percentage of γ-H2AX positive cells at 24 hours following 
treatment of E2 GSCs with various concentrations of SCH, error bars show mean + SEM, 
n≥3 independent experiments, *p<0.05.  (C) Representative flow cytometry plots from E2 
bulk cells with summary comparing the percentage of γ-H2AX population to GSCs at 24 
hours following 3µM SCH and 5Gy IR treatment.  (D) Representative histogram plots from 
flow cytometry data showing the percentage of mitotic cells with high γ-H2AX at 24 hours 
following treatment with 3µM SCH and 5Gy IR.  (E) Summary of flow cytometry data 
showing percentage of mitotic cells with high γ-H2AX at 24 hours following treatment of E2 
GSC with various concentrations of SCH, error bars show  mean + SEM, n≥3 independent 
experiments, *p<0.05, **p<0.01. (F) Representative immunofluorescence images showing p-
His H3 positive mitotic cells (green) with no/low γ-H2AX  (red, top panel) or high γ-H2AX 
(middle panel).   Image of cell undergoing mitotic catastrophe as marked by nuclear blebbing 
and high γ-H2AX (bottom panel).  DAPI nuclear stain in blue.  Bar charts summarising 
immunofluorescence data from analysis of ∼75 mitotic cells.  (G) Representative image and 
summary of the percentage of E2 GSCs with micronuclei (arrows) following treatment with 
3µM SCH and IR  for 24 hours, error bars show mean + SEM from scoring ∼ 500 nuclei, 
*p<0.05, **p<0.01). 
Figure 6. GSC show enhanced DNA repair capacity following irradiation and/or CHK1 
inhibition 
Summary of flow cytometry data showing the percentage of (A) γ-H2AX positive cells, (B) 
mitotic cells with high γ-H2AX and (C) mitotic catastrophe (arrows) in paired G7 bulk and 
GSC populations at 24 hours following treatment with 3µM SCH and/or 5Gy IR, error bars 
show mean + SEM, n≥3 independent experiments, **p<0.01, **p<0.001. (D)  Bar chart 
summary of the percentage of G7 bulk and GSC with micronuclei following indicated 
treatment combination for 24 hours, error bars show mean + SEM from scoring ∼ 600 nuclei, 
***p<0.001.  (E) Representative immunofluorescence images of E2 GSC and bulk 
populations at 24 hours following 10Gy IR, γ-H2AX foci (green), CENPF (red) and DAPI 
(blue). (F)   Plots showing median  γ-H2AX foci  per nucleus in E2 bulk and GSC CENPF 
positive or negative cells populations from scoring  a minimum 65 (CENPF positive) or 300  
(CENPF negative) nuclei, *p<0.05, **p<0.01. 
 
Figure 7. Enhanced radiosensitisation of GSCs by parallel inhibition of DNA repair 
and cell cycle checkpoint pathways 
(A-B) Clonogenic survival curves in E2 GSC and bulk populations following treatment with 
multiple DDRi in combination with radiation. (B) Summary of SER at 37% survival in paired 
populations with 95% confidence interval, *p<0.05 and NS=non-significant between GSC 
and bulk population. CHK1i data as shown previously in Figure 4E & 4F. (C) Inhibition of IR 
induced G2/M checkpoint activation in E2 GSCs following 5Gy IR treatment in the presence 
of various DDRi, significance relative to DMSO treatment (IR alone) are indicated; *p<0.05, 
**p<0.01, ***p<0.001.  (D) Plots showing median number of γ-H2AX foci in CENPF positive 
cells at 24 hours following treatment with IR in combination with DDRi, minimum of 65 nuclei 
scored; ***p<0.001. (E) Neurosphere formation assay showing significant reduction in the 
number of neurospheres at 4 weeks following ATR+PARP1 inhibition in combination with 
radiation;  **p<0.01, ***p<0.001.  (F) Clonogenic survival curves in E2 cells showing 
significant radiosensitisation of GSC over the bulk population as shown by the SER following 
combined treatment with ATR+PARP inhibitors in combination with radiation.  ATMi data as 
shown in part A and B. 
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